Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2021

View Archived Issues

A different path to specificity for Ras inhibitors

Crinetics opens phase III study of paltusotine to treat acromegaly

LIB Therapeutics initiates phase III studies of lerodalcibep in hypercholesterolemia

BioNTech and Regeneron evaluate the combination of BNT-111 and cemiplimab in melanoma

Anti-CD6 therapy suppresses autoimmunity and enhances cancer cell death

Characterization of HSK-16149, a selective ligand of VGCC alpha2delta subunit

Phase I trial of a vaccine targeting tumor-associated antigens PSA, MUC-1 and brachyury in mCRPC

Adrenaline release immobilizes immune cell responses

Gene variants linked to premenstrual dysphoric disorder

IL-12 immunoconjugate SON-1010 generally well tolerated in cynomolgus monkeys

FDA clears IND application for PF-614-MPAR opioid with overdose protection

Patient dosing begins in phase Ib/II study of CFI-400945 in leukemia

European Commission approves Orladeyo for the prevention of HAE attacks

New model of metabolic syndrome-induced CKD in mice

Janssen Pharmaceutica divulges CB1 and/or CB2 receptor agonists

Esteve Pharmaceuticals patents new analgesics

Monte Rosa Therapeutics discloses new protein cereblon modulators

Heptares Therapeutics presents EP4 receptor antagonists

U.S. researchers discover new CARs against cytomegalovirus

FDA approves Farxiga for chronic kidney disease

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

Researchers identify new markers of treatment response in alcohol use disorder

FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis

Synairgen reports home cohort and combined analysis from phase II trial of SNG-001 in COVID-19

Repare initiates phase I trial of oral PKMYT1 inhibitor RP-6306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...